Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 3487-3487. PMID: 33993427, DOI: 10.1007/s12325-021-01780-0.Peer-Reviewed Original ResearchCorrection to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2226-2228. PMID: 33826091, PMCID: PMC8107069, DOI: 10.1007/s12325-021-01683-0.Peer-Reviewed Original ResearchPatterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Research 2021, 23: 14. PMID: 33514405, PMCID: PMC7844919, DOI: 10.1186/s13058-021-01394-y.Peer-Reviewed Original ResearchConceptsPrior endocrine therapyEndocrine therapyMetastatic breast cancerEffective treatment optionTreatment optionsBreast cancerMedian treatmentMedian OSEE therapyHormone receptor-positive HER2-negative metastatic breast cancerMultivariable Cox proportional hazards regression analysisHER2-negative metastatic breast cancerPrior treatmentCox proportional hazards regression analysisFirst-line therapy initiationProportional hazards regression analysisPrior treatment optionsLines of therapyProportion of patientsKaplan-Meier methodHazards regression analysisPatterns of treatmentElectronic health record-derived dataClinical trial dataOS benefitEffectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA. Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States. Advances In Therapy 2021, 38: 2213-2225. PMID: 33491157, PMCID: PMC8107067, DOI: 10.1007/s12325-020-01613-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerMetastatic breast cancerObjective response rateProgression-free survivalMedian progression-free survivalMedian overall survivalOverall survivalBreast cancerClinical practiceRetrospective chart review studyReal-world clinical experienceReal-world clinical practiceUS indicationEffectiveness of eribulinThird-line therapyPatient chart reviewChart review studyReal-world effectivenessNegative breast cancerElectronic case report formCase report formsEligible patientsMetastatic settingChart reviewTreatment landscape